Search bioRxiv⌕ Search

Biology subjects

Santos, D. M.

Publications and source records attributed to Santos, D. M..

2 recordsLinked to original sources

ST8Sia2 polysialyltransferase protects against infection by Trypanosoma cruzi

Glycosylation is one of the most structurally and functionally diverse co- and post-translational modifications in a cell. Addition and removal of glycans, especially to proteins and lipids, characterize this process which have important implications in several biological processes. In mammals, the repeated enzymatic addition of a sialic acid unit to underlying sialic acids (Sia) by polysialyltransferases, including ST8Sia2, leads to the formation of a sugar polymer called polysialic acid (polySia). The functional relevance of polySia has been extensively demonstrated in the nervous system. However, the role of polysialylation in infection is still poorly explored. Previous reports have shown that Trypanosoma cruzi (T. cruzi), a flagellated parasite that causes Chagas disease (CD), changes host sialylation of glycoproteins. To understand the role of host polySia during T. cruzi infection, we used a combination of in silico and experimental tools. We observed that T. cruzi reduces both the expression of the ST8Sia2 and the polysialylation of target substrates. We also found that chemical and genetic inhibition of host ST8Sia2 increased the parasite load in mammalian cells. These findings suggest a novel approach to interfere with parasite infections through modulation of host polysialylation. AUTHOR SUMMARYGlycosylation is a co- and/or post-translational modification regulated by the addition and removal of glycans. This process shapes the cellular glycome, which in turn, holds significant implications in various biological processes. Trypanosoma cruzi (T. cruzi), the etiological agent of Chagas disease, a globally concerning neglected tropical disease affecting 6 to 8 million individuals worldwide, exerts a profound influence on host glycoprotein sialylation. Remarkably, T. cruzi is incapable of synthesizing sialic acid (Sia) and relies on acquiring it from host glycoconjugates. In mammals, the formation of polysialic acid (polySia) is mediated by polysialyltransferases, such as ST8Sia2. The functional relevance of polySia has been extensively documented in the nervous system. Nevertheless, its role within the context of infectious processes remains largely unexplored. Herein, we demonstrate that in T. cruzi-infected host cells, the expression of the ST8Sia2 enzyme is downregulated, resulting in diminished levels of polysialylation. Furthermore, a reduction in the levels of NCAM1 and SCN5A was observed, which can be attributed to the decreased host polysialylation. Moreover, enzymatic removal of polySia, along with chemical inhibition and genetic silencing of ST8Sia2, led to a marked increase in the number of intracellular parasites. We posit that ST8Sia2 inhibition favors T. cruzi infection, thereby elucidating novel avenues for understanding the mechanisms associated with Chagas disease pathogenesis, prominently featuring the pivotal role of host polysialylation.

microbiology↗

Screening the human druggable genome identifies ABHD17B as an anti-fibrotic target in hepatic stellate cells

Hepatic stellate cells (HSCs) are activated with chronic liver injury and transdifferentiate into myofibroblasts, which produce excessive extracellular matrices that form the fibrotic scar. While the progression of fibrosis is understood to be the cause of end-stage liver disease, there are no approved therapies directed at interfering with the activity of HSC myofibroblasts. We performed a high-throughput small interfering RNA (siRNA) screen in primary human HSC myofibroblasts to identify gene products necessary for the fibrotic phenotype of HSCs. We found that depletion of ABHD17B promotes the inactivation of HSCs, characterized by reduced COL1A1 and ACTA2 expression and accumulation of lipid droplets. Mice deficient for Abhd17b are also protected from fibrosis in the setting of in vivo liver injury. While ABHD17B is a depalmitoylase, our data suggest that ABHD17B promotes fibrosis through pathways independent of depalmitoylation that include interaction with MYO1B to modulate gene expression and HSC migration. Together, our results provide an analysis of the phenotypic consequences for siRNAs targeting RNAs from >9,500 genes in primary human HSCs and identify ABHD17B as a potential therapeutic target to inhibit liver fibrosis.

cell biology↗